Aclaris Therapeutis (ACRS) PT Lowered to $34 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Aclaris Therapeutics (ACRS) Prices 8.6645M Share Common Offering at $10.75/Sh
October 18, 2018 5:45 AM EDTAclaris Therapeutics, Inc. (NASDAQ: ACRS) today announced the pricing of its underwritten public offering of 8,645,000 shares of its common stock at a price to the public of $10.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to... More
Aclaris Therapeutics (ACRS) Announces Proposed Common Share Offering
October 17, 2018 4:01 PM EDTAclaris Therapeutics, Inc. (Nasdaq: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology and immunology, today announced that it intends to offer and sell, subject to market... More
